# Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

> **NCT05759572** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 145 (estimated)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Dalpiciclib
- **DRUG:** Fulvestrant/AI

## Key facts

- **NCT ID:** NCT05759572
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2025-11-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 145 (ESTIMATED)
- **Last updated:** 2024-02-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05759572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05759572, "Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05759572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*